Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Square Pharmaceuticals's Enterprise Value is BDT131,361 Mil.
Square Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT13,979 Mil. Therefore, Square Pharmaceuticals's EV-to-FCF for today is 9.40.
The historical rank and industry rank for Square Pharmaceuticals's EV-to-FCF or its related term are showing as below:
DHA:SQURPHARMA'
s EV-to-FCF Range Over the Past 10 Years
Min: 8.34 Med: 19.8 Max: 50.16
Current: 9.45
During the past 13 years, the highest EV-to-FCF of Square Pharmaceuticals was 50.16. The lowest was 8.34. And the median was 19.80.
DHA:SQURPHARMA's EV-to-FCF is ranked better than 80.11% of 568
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs DHA:SQURPHARMA: 9.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Square Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Square Pharmaceuticals's share price for today is BDT214.70.
Square Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT29.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Square Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Square Pharmaceuticals's EV-to-FCF falls into.
Square Pharmaceuticals's current Enterprise Value is BDT131,361 Mil.
Square Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT13,979 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Square Pharmaceuticals (DHA:SQURPHARMA) has a EV-to-FCF of 9.40 as of Sep. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Square Pharmaceuticals and its competitors. This is 53% below median its historical median of 19.80. Over the past decade, Square Pharmaceuticals' EV-to-FCF has ranged from 8.34 to 50.16. According to the industry distribution chart, Square Pharmaceuticals ranks #113 out of 568 companies in the Drug Manufacturers industry, placing it in the top 19.9%.
Is Square Pharmaceuticals' EV-to-FCF too high?
Square Pharmaceuticals' current EV-to-FCF of 9.40 is 53% below median its 10-year median of 19.80. Over the past 10 years, this metric has ranged from a low of 8.34 to a high of 50.16. The Drug Manufacturers industry median EV-to-FCF is 20.11. Square Pharmaceuticals' value of 9.40 is 53.3% below this industry median. Based on the distribution chart, Square Pharmaceuticals ranks #113 out of 568 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Square Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Square Pharmaceuticals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Square Pharmaceuticals ranks #113 out of 568 companies for EV-to-FCF. This places Square Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.11. Square Pharmaceuticals' value of 9.40 is 53.3% below this benchmark. Historically, Square Pharmaceuticals' own EV-to-FCF has ranged from 8.34 to 50.16 over the past decade. While the company's 10-year median is 19.80 vs. the industry median of 20.11, Square Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Square Pharmaceuticals's current EV-to-FCF of 9.40 is 53.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Square Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Square Pharmaceuticals's current EV-to-FCF is 9.40, which is 53% below median its own 10-year median of 19.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Square Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Square Pharmaceuticals (DHA:SQURPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is BDT219.96, compared to a current price of BDT214.70 — trading 2.4% below its estimated fair value. The current EV-to-FCF is 9.40, which is 53% below median its 10-year median of 19.80 and 53.3% below the Drug Manufacturers industry median of 20.11. Square Pharmaceuticals' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Square Pharmaceuticals (DHA:SQURPHARMA), the current EV-to-FCF is 9.40 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96.
GuruFocus considers Square Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:SQURPHARMA:
EV-to-FCF: 9.40 (53% below median its 10-year median of 19.80)
GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
Industry Position: 53.3% below the Drug Manufacturers median (#113 of 568)
No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score
Get the complete analysis for DHA:SQURPHARMA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:SQURPHARMA has been successfully added to your 
